Zalutumumab 

Zalutumumab is a high affinity, completely human IgG1 monoclonal antibody targeting EGFR. Zalutumumab binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab binds with IgG and its Fab fragment with EC₅₀s of 7 and 19 nM, respectively. Zalutumumab can be used for the research of cancer^[1][2][3].

Zalutumumab (0-1 μM; 60 min) effectively blocks EGF-induced EGFR activation with an IC₅₀ value of 1.3 nM^[2].
Zalutumumab (0-1 μM; 96 h) affects proliferation of A431 cells^[2].
Zalutumumab (10 μg/mL; 24 h) induces a comparable percentage of specificlysis of A431 cells with mouse macrophages^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Zalutumumab (5 mg/kg; i.p. 2 h after tumor induction) affects tumor growth in A431 xenograft models^[3].
Zalutumumab (0.5 and 5 mg/kg; i.p. once ) delays tumor growth when mice with tumor volumes of 80-100 mm^3[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

667901-13-5

Liquid

Colorless to light yellow

[Zalutumumab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Schick U, et al. Zalutumumab in head and neck cancer. Expert Opin Biol Ther. 2012 Jan;12(1):119-25.  [Content Brief]

  [2]. Lammerts van Bueren JJ, et al. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility. Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6109-14.  [Content Brief]

  [3]. Overdijk MB, et al. Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. J Immunol. 2011 Sep 15;187(6):3383-90.  [Content Brief]